Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

Is Now The Perfect Time To Buy AstraZeneca plc, Greggs plc And Stanley Gibbons Group PLC?

Are these 3 stocks ripe for investment? AstraZeneca plc (LON: AZN), Greggs plc (LON: GRG) and Stanley Gibbons Group PLC (LON: SGI)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Turning companies around from disappointing financial performance to superb profitability is never an easy task. After all, there is usually a very good reason for their bottom lines falling, whether that is a change in customer tastes, a recession or poor decisions by management which have caused the business to become uncompetitive. And, even if the right strategy is put in place, it usually takes a considerable amount of time for even the best of companies to mount a successful comeback.

One stock which is very much on the up is AstraZeneca (LSE: AZN). It has endured a very challenging period of time with a number of key, blockbuster drugs coming off patent and being exposed to generic competition. However, it was a poor response by the business which led to its downfall, since it lacked a strong pipeline of new drugs to take the places of the ones which lost patent protection. Furthermore, policies such as a major share buyback were using up vital cash resources which could have been better spent on improving the company’s long term outlook.

However, under a different management team, AstraZeneca has got its house in order. It has embarked on a highly successful acquisition spree, with its sound balance sheet and excellent cash flow being used to bring on board a number of new drugs and potential treatments which, in years to come, could become blockbuster drugs for the business. And, while the company’s share price has soared by 46% since the start of 2013 (while also paying a yield of 6.1% throughout the period), its shares trade on a relatively appealing price to earnings (P/E) ratio of 15.4.

Also making a successful turnaround is high-street food business Greggs (LSE: GRG). It lost its way under previous management, with the business attempting to diversify its offering through more upmarket coffee shops and a range of chilled/frozen foods on sale in supermarkets. In other words, it appeared to lose focus on its core offering but, under a different management team, Greggs has become a more efficient and simple business. For example, it has closed unprofitable stores, improved its supply chain and focused on giving customers what they want: good value food in convenient locations.

Furthermore, today’s update from Greggs is very positive. It has reported strong sales in a low inflation environment and expects its full-year results to be ahead of market expectations. As such, its shares are up by 6% today, making it a gain of 56% since the turn of the year.

However, Greggs is likely to see margins squeezed in future years from the impact of the new living wage. And, while it already pays its staff a higher rate than the minimum wage, for a business which is focused on value it may be unable to pass all of the additional costs on to consumers.

Meanwhile, collectibles company Stanley Gibbons (LSE: SGI) appears to be in need of a turnaround, with its shares slumping by 27% today after a profit warning. It continues to struggle with a slowing Asian economy and, while it states in today’s update that its second half performance will be much better than its first, margins are coming under increasing pressure.

As a result, its short term performance is likely to be rather disappointing and its shares may continue the run which has seen them fall by 62% since the turn of the year. However, Stanley Gibbons remains a financially sound, niche business which has long term potential to recover as the world economy stabilises. And, with it having a price to book value (P/B) ratio of just 0.8, it appears to be worth buying for the long term.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Rolls-Royce's Pearl 10X engine series
Investing Articles

Can the Rolls-Royce share price do it again in 2026?

Can the Rolls-Royce share price do it again? The FTSE 100 company has been a star performer in recent years…

Read more »

Businessman hand flipping wooden block cube from 2024 to 2025 on coins
Investing Articles

After huge gains for S&P 500 tech stocks in 2025, here are 4 moves I’m making to protect my ISA and SIPP

Gains from S&P tech stocks have boosted Edward Sheldon’s retirement accounts this year. Here’s what he’s doing now to reduce…

Read more »

View of Lake District. English countryside with fields in the foreground and a lake and hills behind.
Investing Articles

With a 3.2% yield, has the FTSE 100 become a wasteland for passive income investors?

With dividend yields where they are at the moment, should passive income investors take a look at the bond market…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

Should I add this dynamic FTSE 250 newcomer to my Stocks and Shares ISA?

At first sight, a UK bank that’s joining the FTSE 250 isn’t anything to get excited by. But beneath the…

Read more »

Investing Articles

£10,000 invested in BT shares 3 months ago is now worth

BT shares have been volatile lately and Harvey Jones is wondering whether now is a good time to buy the…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

After a 66% fall, this under-the-radar growth stock looks like brilliant value to me

Undervalued growth stocks can be outstanding investments. And Stephen Wright thinks he has one in a company analysts seem to…

Read more »

Content white businesswoman being congratulated by colleagues at her retirement party
Investing Articles

Don’t ‘save’ for retirement! Invest in dirt cheap UK shares to aim for a better lifestyle

Investing in high-quality and undervalued UK shares could deliver far better results when building wealth for retirement. Here's how.

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

1 growth and 1 income stock to kickstart a passive income stream

Diversification is key to achieving sustainable passive income. Mark Hartley details two broadly different stocks for beginners.

Read more »